A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery
The programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) is a well-established inhibitory immune checkpoint axis in triple-negative breast cancer (TNBC). Growing evidence indicates that tumoral PD-L1 can lead to TNBC development. Although conventional immune checkpoint inhibitors...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Genes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4425/12/8/1206 |
| _version_ | 1797523746949431296 |
|---|---|
| author | Mahdi Abdoli Shadbad Sahar Safaei Oronzo Brunetti Afshin Derakhshani Parisa Lotfinejad Ahad Mokhtarzadeh Nima Hemmat Vito Racanelli Antonio Giovanni Solimando Antonella Argentiero Nicola Silvestris Behzad Baradaran |
| author_facet | Mahdi Abdoli Shadbad Sahar Safaei Oronzo Brunetti Afshin Derakhshani Parisa Lotfinejad Ahad Mokhtarzadeh Nima Hemmat Vito Racanelli Antonio Giovanni Solimando Antonella Argentiero Nicola Silvestris Behzad Baradaran |
| author_sort | Mahdi Abdoli Shadbad |
| collection | DOAJ |
| description | The programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) is a well-established inhibitory immune checkpoint axis in triple-negative breast cancer (TNBC). Growing evidence indicates that tumoral PD-L1 can lead to TNBC development. Although conventional immune checkpoint inhibitors have improved TNBC patients’ prognosis, their effect is mainly focused on improving anti-tumoral immune responses without substantially regulating oncogenic signaling pathways in tumoral cells. Moreover, the conventional immune checkpoint inhibitors cannot impede the de novo expression of oncoproteins, like PD-L1, in tumoral cells. Accumulating evidence has indicated that the restoration of specific microRNAs (miRs) can downregulate tumoral PD-L1 and inhibit TNBC development. Since miRs can target multiple mRNAs, miR-based gene therapy can be an appealing approach to inhibit the de novo expression of oncoproteins, like PD-L1, restore anti-tumoral immune responses, and regulate various intracellular singling pathways in TNBC. Therefore, we conducted the current systematic review based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) to provide a comprehensive and unbiased synthesis of currently available evidence regarding the effect of PD-L1-inhibiting miRs restoration on TNBC development and tumor microenvironment. For this purpose, we systematically searched the Cochrane Library, Embase, Scopus, PubMed, ProQuest, Web of Science, Ovid, and IranDoc databases to obtain the relevant peer-reviewed studies published before 25 May 2021. Based on the current evidence, the restoration of miR-424-5p, miR-138-5p, miR-570-3p, miR-200c-3p, miR-383-5p, miR-34a-5p, miR-3609, miR-195-5p, and miR-497-5p can inhibit tumoral PD-L1 expression, transform immunosuppressive tumor microenvironment into the pro-inflammatory tumor microenvironment, inhibit tumor proliferation, suppress tumor migration, enhance chemosensitivity of tumoral cells, stimulate tumor apoptosis, arrest cell cycle, repress the clonogenicity of tumoral cells, and regulate various oncogenic signaling pathways in TNBC cells. Concerning the biocompatibility of biomimetic carriers and the valuable insights provided by the single-cell sequencing technologies, single-cell sequencing-guided biomimetic delivery of these PD-L1-inhibiting miRs can decrease the toxicity of traditional approaches, increase the specificity of miR-delivery, enhance the efficacy of miR delivery, and provide the affected patients with personalized cancer therapy. |
| first_indexed | 2024-03-10T08:47:25Z |
| format | Article |
| id | doaj.art-0c427654b2c9422e8c2507f2bff05a21 |
| institution | Directory Open Access Journal |
| issn | 2073-4425 |
| language | English |
| last_indexed | 2024-03-10T08:47:25Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Genes |
| spelling | doaj.art-0c427654b2c9422e8c2507f2bff05a212023-11-22T07:46:03ZengMDPI AGGenes2073-44252021-08-01128120610.3390/genes12081206A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic DeliveryMahdi Abdoli Shadbad0Sahar Safaei1Oronzo Brunetti2Afshin Derakhshani3Parisa Lotfinejad4Ahad Mokhtarzadeh5Nima Hemmat6Vito Racanelli7Antonio Giovanni Solimando8Antonella Argentiero9Nicola Silvestris10Behzad Baradaran11Research Center for Evidence-Based Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614766, IranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 5165665811, IranMedical Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, ItalyImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 5165665811, IranResearch Center for Evidence-Based Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614766, IranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 5165665811, IranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 5165665811, IranDepartment of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari “Aldo Moro”, 70124 Bari, ItalyMedical Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, ItalyMedical Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, ItalyMedical Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, ItalyImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 5165665811, IranThe programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) is a well-established inhibitory immune checkpoint axis in triple-negative breast cancer (TNBC). Growing evidence indicates that tumoral PD-L1 can lead to TNBC development. Although conventional immune checkpoint inhibitors have improved TNBC patients’ prognosis, their effect is mainly focused on improving anti-tumoral immune responses without substantially regulating oncogenic signaling pathways in tumoral cells. Moreover, the conventional immune checkpoint inhibitors cannot impede the de novo expression of oncoproteins, like PD-L1, in tumoral cells. Accumulating evidence has indicated that the restoration of specific microRNAs (miRs) can downregulate tumoral PD-L1 and inhibit TNBC development. Since miRs can target multiple mRNAs, miR-based gene therapy can be an appealing approach to inhibit the de novo expression of oncoproteins, like PD-L1, restore anti-tumoral immune responses, and regulate various intracellular singling pathways in TNBC. Therefore, we conducted the current systematic review based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) to provide a comprehensive and unbiased synthesis of currently available evidence regarding the effect of PD-L1-inhibiting miRs restoration on TNBC development and tumor microenvironment. For this purpose, we systematically searched the Cochrane Library, Embase, Scopus, PubMed, ProQuest, Web of Science, Ovid, and IranDoc databases to obtain the relevant peer-reviewed studies published before 25 May 2021. Based on the current evidence, the restoration of miR-424-5p, miR-138-5p, miR-570-3p, miR-200c-3p, miR-383-5p, miR-34a-5p, miR-3609, miR-195-5p, and miR-497-5p can inhibit tumoral PD-L1 expression, transform immunosuppressive tumor microenvironment into the pro-inflammatory tumor microenvironment, inhibit tumor proliferation, suppress tumor migration, enhance chemosensitivity of tumoral cells, stimulate tumor apoptosis, arrest cell cycle, repress the clonogenicity of tumoral cells, and regulate various oncogenic signaling pathways in TNBC cells. Concerning the biocompatibility of biomimetic carriers and the valuable insights provided by the single-cell sequencing technologies, single-cell sequencing-guided biomimetic delivery of these PD-L1-inhibiting miRs can decrease the toxicity of traditional approaches, increase the specificity of miR-delivery, enhance the efficacy of miR delivery, and provide the affected patients with personalized cancer therapy.https://www.mdpi.com/2073-4425/12/8/1206programmed death-ligand 1PD-L1triple-negative breast cancerTNBCmicroRNAmicroRNA-based gene-therapy |
| spellingShingle | Mahdi Abdoli Shadbad Sahar Safaei Oronzo Brunetti Afshin Derakhshani Parisa Lotfinejad Ahad Mokhtarzadeh Nima Hemmat Vito Racanelli Antonio Giovanni Solimando Antonella Argentiero Nicola Silvestris Behzad Baradaran A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery Genes programmed death-ligand 1 PD-L1 triple-negative breast cancer TNBC microRNA microRNA-based gene-therapy |
| title | A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery |
| title_full | A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery |
| title_fullStr | A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery |
| title_full_unstemmed | A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery |
| title_short | A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery |
| title_sort | systematic review on the therapeutic potentiality of pd l1 inhibiting micrornas for triple negative breast cancer toward single cell sequencing guided biomimetic delivery |
| topic | programmed death-ligand 1 PD-L1 triple-negative breast cancer TNBC microRNA microRNA-based gene-therapy |
| url | https://www.mdpi.com/2073-4425/12/8/1206 |
| work_keys_str_mv | AT mahdiabdolishadbad asystematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT saharsafaei asystematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT oronzobrunetti asystematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT afshinderakhshani asystematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT parisalotfinejad asystematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT ahadmokhtarzadeh asystematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT nimahemmat asystematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT vitoracanelli asystematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT antoniogiovannisolimando asystematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT antonellaargentiero asystematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT nicolasilvestris asystematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT behzadbaradaran asystematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT mahdiabdolishadbad systematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT saharsafaei systematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT oronzobrunetti systematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT afshinderakhshani systematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT parisalotfinejad systematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT ahadmokhtarzadeh systematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT nimahemmat systematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT vitoracanelli systematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT antoniogiovannisolimando systematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT antonellaargentiero systematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT nicolasilvestris systematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery AT behzadbaradaran systematicreviewonthetherapeuticpotentialityofpdl1inhibitingmicrornasfortriplenegativebreastcancertowardsinglecellsequencingguidedbiomimeticdelivery |